The June, 2011 issue of Nature Drug Discovery has a interesting short article based on a survey conducted by our good friends at PharmaVentures. The authors surveyed 180 business development…
We posted in February the news that Pfizer was closing their large R&D facility in Kent, UK. It was with some surprise that we learn that the facility is already…
There is a fascinating discussion taking place over at Derek Lowe's blog today on one-man drug companies: ...some of them are not quite down to one person, but you can…
Today we learn that Rigel has raised $130 million in financing, in part, to develop candidates in rheumatoid arthritis and other areas. But, as reported by Xconomy, the real gem…
This week we learn that two novel pain medications will never see the light of day: Novartis had reached the market with the COX-II inhibitor Prexige (rebranded as the unusually…
We regret that we were unable to attend the panel discussions at BioTrinity last week. However, an excellent summary was posted on the PharmaPhorum web site. Of note: 1. Investment…
Fred Frank, a highly respected investment banker, greeted us on Tuesday morning with this missive: Venture capitalists, who make high-risk investments in start-ups, are tired of waiting years for biotech companies…
Drug development costs of $1 billion are often quoted. A new study estimates costs to be much lower, based on a different statistical approach.
We were intrigued by a comment made on Twitter regarding pharma employee involvement with social media: [It's] important to allow all employees to engage within guidelines and not restrict with…
This evening, @AstraZenecaUS held a fascinating Twitter chat (hashtag #RxSave). The focus of the discussion was on pharma-sponsored prescription savings plans. AZ was also looking for advice on how to…